-
Something wrong with this record ?
Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia
E. Vavrova, B. Kantorova, B. Vonkova, J. Kabathova, H. Skuhrova-Francova, E. Diviskova, O. Letocha, J. Kotaskova, Y. Brychtova, M. Doubek, J. Mayer, S. Pospisilova,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV15-31834A
MZ0
CEP Register
- MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell genetics MeSH
- Humans MeSH
- Mutation * MeSH
- DNA Mutational Analysis methods MeSH
- Peptide Fragments analysis MeSH
- Receptor, Notch1 genetics MeSH
- High-Throughput Nucleotide Sequencing MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The hotspot c.7541_7542delCT NOTCH1 mutation has been proven to have a negative clinical impact in chronic lymphocytic leukemia (CLL). However, an optimal method for its detection has not yet been specified. The aim of our study was to examine the presence of the NOTCH1 mutation in CLL using three commonly used molecular methods. Sanger sequencing, fragment analysis and allele-specific PCR were compared in the detection of the c.7541_7542delCT NOTCH1 mutation in 201 CLL patients. In 7 patients with inconclusive mutational analysis results, the presence of the NOTCH1 mutation was also confirmed using ultra-deep next generation sequencing. The NOTCH1 mutation was detected in 15% (30/201) of examined patients. Only fragment analysis was able to identify all 30 NOTCH1-mutated patients. Sanger sequencing and allele-specific PCR showed a lower detection efficiency, determining 93% (28/30) and 80% (24/30) of the present NOTCH1 mutations, respectively. Considering these three most commonly used methodologies for c.7541_7542delCT NOTCH1 mutation screening in CLL, we defined fragment analysis as the most suitable approach for detecting the hotspot NOTCH1 mutation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016395
- 003
- CZ-PrNML
- 005
- 20230718134125.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2017.08.001 $2 doi
- 035 __
- $a (PubMed)28837890
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vavrova, Eva $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic.
- 245 10
- $a Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia / $c E. Vavrova, B. Kantorova, B. Vonkova, J. Kabathova, H. Skuhrova-Francova, E. Diviskova, O. Letocha, J. Kotaskova, Y. Brychtova, M. Doubek, J. Mayer, S. Pospisilova,
- 520 9_
- $a The hotspot c.7541_7542delCT NOTCH1 mutation has been proven to have a negative clinical impact in chronic lymphocytic leukemia (CLL). However, an optimal method for its detection has not yet been specified. The aim of our study was to examine the presence of the NOTCH1 mutation in CLL using three commonly used molecular methods. Sanger sequencing, fragment analysis and allele-specific PCR were compared in the detection of the c.7541_7542delCT NOTCH1 mutation in 201 CLL patients. In 7 patients with inconclusive mutational analysis results, the presence of the NOTCH1 mutation was also confirmed using ultra-deep next generation sequencing. The NOTCH1 mutation was detected in 15% (30/201) of examined patients. Only fragment analysis was able to identify all 30 NOTCH1-mutated patients. Sanger sequencing and allele-specific PCR showed a lower detection efficiency, determining 93% (28/30) and 80% (24/30) of the present NOTCH1 mutations, respectively. Considering these three most commonly used methodologies for c.7541_7542delCT NOTCH1 mutation screening in CLL, we defined fragment analysis as the most suitable approach for detecting the hotspot NOTCH1 mutation.
- 650 _2
- $a mutační analýza DNA $x metody $7 D004252
- 650 _2
- $a vysoce účinné nukleotidové sekvenování $7 D059014
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x genetika $7 D015451
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a peptidové fragmenty $x analýza $7 D010446
- 650 _2
- $a receptor Notch1 $x genetika $7 D051881
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kantorova, Barbara $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Kunt Vonková, Barbara $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic. $7 xx0248649
- 700 1_
- $a Kabathova, Jitka $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Skuhrova-Francova, Hana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Diviskova, Eva $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Letocha, Ondrej $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Kotaskova, Jana $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Brychtova, Yvona $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Doubek, Michael $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Mayer, Jiri $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology (CEITEC) and Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Cernopolni 9, CZ-613 00 Brno, Czech Republic. Electronic address: sarka.pospisilova@ceitec.muni.cz.
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 60, č. - (2017), s. 145-150
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28837890 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20230718134122 $b ABA008
- 999 __
- $a ok $b bmc $g 1300019 $s 1013235
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 60 $c - $d 145-150 $e 20170807 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- GRA __
- $a NV15-31834A $p MZ0
- LZP __
- $a Pubmed-20180515